索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]胡晓惠,牛梦瑶,刘志浩,等.射血分数保留的心力衰竭：挑战与机遇[J].国际心血管病杂志,2023,06:362-364.
点击复制

射血分数保留的心力衰竭：挑战与机遇(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年06期
页码:
362-364
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
-
作者:
胡晓惠; 牛梦瑶; 刘志浩; 张静
吉林大学第二医院心血管内科
Author(s):
-
关键词:
射血分数保留的心力衰竭; 药物治疗; 运动康复; 房间隔分流装置
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.06.007
文献标识码:
-
摘要:
射血分数保留的心力衰竭（HFpEF）的病理生理机制尚未完全明确。不同于射 血分数降低的心力衰竭（HFrEF），HFpEF 的治疗手段有限。该文主要介绍钠- 葡萄糖协同 转运蛋白2（SGLT-2）抑制剂、血管紧张素受体脑啡肽酶抑制（ARNI）、抗纤维化、抗炎 等药物治疗，以及运动康复、房间隔分流器等非药物治疗在HFpEF 中的应用。
Abstract:
-

参考文献/References

[1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2022, 145(18):e895-e1032.
[2] Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2):117-128.
[3] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16):1451-1461.
[4] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12):1089-1098.
[5] Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial[J]. Nat Med, 2021, 27(11):1954-1960.
[6] Solomon SD, McMurray JJV, Anand IS, et al. Angiotensinneprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17):1609-1620.
[7] Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone[J]. Circulation, 2015, 132(5):402-414.
[8] Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL study[J]. JACC Cardiovasc Imaging, 2015, 8(6):656-665.
[9] Lewis GA, Rosala-Hallas A, Dodd S, et al. Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction[J]. Int J Cardiovasc Imaging, 2022, 38(7):1569-1578.
[10] Kessler EL, Oerlemans MIFJ, van den Hoogen P, et al. Immunomodulation in heart failure with preserved ejection fraction: current state and future perspectives[J]. J Cardiovasc Transl Res, 2021, 14(1):63-74.
[11] Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)[J]. Am J Cardiol, 2014, 113(2):321-327.
[12] Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail, 2018, 11(8):e005036.
[13] Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure[J]. Circulation, 2019, 139(10):1289-1299.
[14] Shen S, Duan J, Hu J, et al. Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction[J]. Eur J Pharmacol, 2022, 929:175126.
[15] Marume K, Takashio S, Nagai T, et al. Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease—report from the JASPER study[J]. Circ J, 2019, 83(2):357-367.
[16] Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial[J]. JAMA, 2016, 315(1):36-46.
[17] Kamiya K, Sato Y, Takahashi T, et al. Multidisciplinary cardiac rehabilitation and long-term prognosis in patients with heart failure[J]. Circ Heart Fail, 2020, 13(10):e006798.
[18] 中国医师协会心血管内科医师分会结构性心脏病专业委员 会. 房间隔分流器治疗射血分数保留心力衰竭：中国专家 认识和建议[J]. 中国介入心脏病学杂志, 2020, 28(12):661- 666.
[19] Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF Ⅱ): a randomised, multicentre, blinded, sham-controlled trial[J]. Lancet, 2022, 399(10330):1130-1140.
[20] Guimar?es L, Bergeron S, Bernier M, et al. Interatrial shunt with the second-generation V-wave system for patients with advanced chronic heart failure[J]. Euro Intervention, 2020, 15(16):1426-1428.
[21] Paitazoglou C, ?zdemir R, Pfister R, et al. The AFRPRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction[J]. Euro Intervention, 2019, 15(5):403-410.
[22] 尚小珂, 张长东, 陈澍, 等. 首例心房分流器置入术治疗 射血分数保留的心衰[J]. 中华胸心血管外科杂志, 2021, 37(5):309-311.
[23] Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart[J]. Nat Clin Pract Cardiovasc Med, 2005, 2(10):536- 543.
[24] Iacobellis G. Epicardial adipose tissue in contemporary cardiology[J]. Nat Rev Cardiol, 2022, 19(9):593-606.
[25] Rohatgi A, Westerterp M, von Eckardstein A, et al. HDL in the 21st century: a multifunctional roadmap for future HDL research[J]. Circulation, 2021, 143(23):2293-2309.
[26] Mishra M, Muthuramu I, Aboumsallem JP, et al. Reconstituted HDL (milano) treatment efficaciously reverses heart failure with preserved ejection fraction in mice[J]. Int J Mol Sci, 2018, 19(11):3399.
[27] Elkholey K, Niewiadomska M, Morris L, et al. Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its antiinflammatory effects[J]. Circ Heart Fail, 2022, 15(8):e009288.

备注/Memo

备注/Memo:
通信作者：张静， E-mail：Zhj_yuan@hotmail.com
更新日期/Last Update: 2023-11-20